Corticosteroids for Castleman Disease

Corticosteroids are a group of drugs related to hormones made in the body by the adrenal glands. These drugs weaken the immune system, so they are useful in treating people with certain immune system diseases and cancers that develop from immune system cells, such as lymphomas.

In some patients with multicentric Castleman disease (CD), these drugs can be helpful, either alone or along with chemotherapy.

Corticosteroids are often taken as pills, but they can also be injected into a vein. Prednisone is the corticosteroid pill most often used to treat CD.

Side effects of corticosteroids (especially long-term use) can include increased blood sugar (which can lead to diabetes), mood changes, increased risk of infections, weakened bones, fatigue, muscle weakness, weight gain, fluid retention, and high blood pressure. Most of these side effects improve after the drug is stopped.

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpes virus-associated multicentric Castleman disease. Cancer Sci. 2017;9 [Epub ahead of print]. 

National Cancer Institute. Physician Data Query (PDQ). AIDS-related lymphoma treatment. 10/02/2015. Accessed at:  on January 11, 2018. 

National Cancer Institute. Castleman disease. Accessed at on
January 10, 2018. 

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017. Accessed at  on January 11, 2018 . 

National Organization for Rare Disorders. Castleman disease. Accessed at on January 5, 2018. 

van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):89-106. 

Last Revised: February 5, 2018

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.